AML Flashcards
1
Q
FLT3 ITD prognostic factor
A
Similar response rate as WT
but higher rates of relapse
poor OS
higher leukemic burden
2
Q
FLT3- ITD high allelic ratio effect on WBC
A
Leukocytosis
3
Q
FLT3 and MDS
A
Is more common in AML secondary to MDS
4
Q
Prevalence of FLT ITD
A
25%
> 30% in patients > 55 years
5
Q
Addition of GO to 3+7 benefit
A
Beneficial in favorable and intermediate risk
Women
Age < 70
non FLT3 pts
6
Q
SE of GO
A
liver toxicity
increased SOS after ASCT
7
Q
Midostaurin trial for approval in 1st line
A
RATIFY
ages 18-59
8
Q
Oral azacitidine for maintenance in ND-AML
A
After high intensity Tx.
For intermediate-high risk pts not eligible for ASCT
